Products

Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.

Connect With Us

All Products (153)

Quick filters: Solid Tumour Hematologic Both Name A-Z Name Z-A

Therapeutic Areas

Sort by

Clear all filters

Molecule	Drug Class / Mechanism	Oncology Type
Ziftomenib	EZH2 / Menin Inhibitor	Hematologic
Molecule Ziftomenib Therapeutic Category Targeted Therapy Oncology Type Hematologic Drug Class / Mechanism EZH2 / Menin Inhibitor
Bleximenib	EZH2 / Menin Inhibitor	Hematologic
Molecule Bleximenib Therapeutic Category Targeted Therapy Oncology Type Hematologic Drug Class / Mechanism EZH2 / Menin Inhibitor
Enzomenib	EZH2 / Menin Inhibitor	Hematologic
Molecule Enzomenib Therapeutic Category Targeted Therapy Oncology Type Hematologic Drug Class / Mechanism EZH2 / Menin Inhibitor
Rituximab	Anti-CD20 mAb	Hematologic (Lymphoma/CLL)
Molecule Rituximab Therapeutic Category Immunotherapy (Monoclonal Antibody) Oncology Type Hematologic (Lymphoma/CLL) Drug Class / Mechanism Anti-CD20 mAb
Obinutuzumab	Anti-CD20 mAb	Hematologic (Lymphoma/CLL)
Molecule Obinutuzumab Therapeutic Category Immunotherapy (Monoclonal Antibody) Oncology Type Hematologic (Lymphoma/CLL) Drug Class / Mechanism Anti-CD20 mAb
Ofatumumab	Anti-CD20 mAb	Hematologic (Lymphoma/CLL)
Molecule Ofatumumab Therapeutic Category Immunotherapy (Monoclonal Antibody) Oncology Type Hematologic (Lymphoma/CLL) Drug Class / Mechanism Anti-CD20 mAb
Ublituximab	Anti-CD20 mAb	Hematologic (Lymphoma/CLL)
Molecule Ublituximab Therapeutic Category Immunotherapy (Monoclonal Antibody) Oncology Type Hematologic (Lymphoma/CLL) Drug Class / Mechanism Anti-CD20 mAb
Veltuzumab	Anti-CD20 mAb	Hematologic (Lymphoma/CLL)
Molecule Veltuzumab Therapeutic Category Immunotherapy (Monoclonal Antibody) Oncology Type Hematologic (Lymphoma/CLL) Drug Class / Mechanism Anti-CD20 mAb
Ocaratuzumab	Anti-CD20 mAb	Hematologic (Lymphoma/CLL)
Molecule Ocaratuzumab Therapeutic Category Immunotherapy (Monoclonal Antibody) Oncology Type Hematologic (Lymphoma/CLL) Drug Class / Mechanism Anti-CD20 mAb
Alemtuzumab	Anti-CD52 mAb	Hematologic (CLL)
Molecule Alemtuzumab Therapeutic Category Immunotherapy (Monoclonal Antibody) Oncology Type Hematologic (CLL) Drug Class / Mechanism Anti-CD52 mAb
Brentuximab Vedotin	ADC	Hematologic
Molecule Brentuximab Vedotin Therapeutic Category Targeted Therapy (Antibody-Drug Conjugate) Oncology Type Hematologic Drug Class / Mechanism ADC
Gemtuzumab Ozogamicin	ADC	Hematologic
Molecule Gemtuzumab Ozogamicin Therapeutic Category Targeted Therapy (Antibody-Drug Conjugate) Oncology Type Hematologic Drug Class / Mechanism ADC

Ziftomenib Targeted Therapy
Therapeutic Category Targeted Therapy Oncology Type Hematologic Drug Class / Mechanism EZH2 / Menin Inhibitor
Bleximenib Targeted Therapy
Therapeutic Category Targeted Therapy Oncology Type Hematologic Drug Class / Mechanism EZH2 / Menin Inhibitor
Enzomenib Targeted Therapy
Therapeutic Category Targeted Therapy Oncology Type Hematologic Drug Class / Mechanism EZH2 / Menin Inhibitor
Rituximab Immunotherapy (Monoclonal Antibody)
Therapeutic Category Immunotherapy (Monoclonal Antibody) Oncology Type Hematologic (Lymphoma/CLL) Drug Class / Mechanism Anti-CD20 mAb
Obinutuzumab Immunotherapy (Monoclonal Antibody)
Therapeutic Category Immunotherapy (Monoclonal Antibody) Oncology Type Hematologic (Lymphoma/CLL) Drug Class / Mechanism Anti-CD20 mAb
Ofatumumab Immunotherapy (Monoclonal Antibody)
Therapeutic Category Immunotherapy (Monoclonal Antibody) Oncology Type Hematologic (Lymphoma/CLL) Drug Class / Mechanism Anti-CD20 mAb
Ublituximab Immunotherapy (Monoclonal Antibody)
Therapeutic Category Immunotherapy (Monoclonal Antibody) Oncology Type Hematologic (Lymphoma/CLL) Drug Class / Mechanism Anti-CD20 mAb
Veltuzumab Immunotherapy (Monoclonal Antibody)
Therapeutic Category Immunotherapy (Monoclonal Antibody) Oncology Type Hematologic (Lymphoma/CLL) Drug Class / Mechanism Anti-CD20 mAb
Ocaratuzumab Immunotherapy (Monoclonal Antibody)
Therapeutic Category Immunotherapy (Monoclonal Antibody) Oncology Type Hematologic (Lymphoma/CLL) Drug Class / Mechanism Anti-CD20 mAb
Alemtuzumab Immunotherapy (Monoclonal Antibody)
Therapeutic Category Immunotherapy (Monoclonal Antibody) Oncology Type Hematologic (CLL) Drug Class / Mechanism Anti-CD52 mAb
Brentuximab Vedotin Targeted Therapy (Antibody-Drug Conjugate)
Therapeutic Category Targeted Therapy (Antibody-Drug Conjugate) Oncology Type Hematologic Drug Class / Mechanism ADC
Gemtuzumab Ozogamicin Targeted Therapy (Antibody-Drug Conjugate)
Therapeutic Category Targeted Therapy (Antibody-Drug Conjugate) Oncology Type Hematologic Drug Class / Mechanism ADC

‹ 1 2 3 4 5 6 … 13 ›

Product Range

Company

Global Network

Products

Ziftomenib

Bleximenib

Enzomenib

Rituximab

Obinutuzumab

Ofatumumab

Ublituximab

Veltuzumab

Ocaratuzumab

Alemtuzumab

Brentuximab Vedotin

Gemtuzumab Ozogamicin

Ziftomenib

Bleximenib

Enzomenib

Rituximab

Obinutuzumab

Ofatumumab

Ublituximab

Veltuzumab

Ocaratuzumab

Alemtuzumab

Brentuximab Vedotin

Gemtuzumab Ozogamicin